NCT05189730 (ETNT) is a Phase 2 clinical trial of Tirelizumab in Esophageal Squamous Cell Carcinoma, sponsored by Sichuan Cancer Hospital and Research Institute.

Who is sponsoring NCT05189730?

NCT05189730 is sponsored by Sichuan Cancer Hospital and Research Institute.

What drugs are being tested in NCT05189730?

Interventions in NCT05189730: Tirelizumab, Paclitaxel, Carboplatin, Neoadiuvant radiotherapy.

What condition does NCT05189730 study?

NCT05189730 studies Esophageal Squamous Cell Carcinoma.

Is NCT05189730 still recruiting?

NCT05189730 is currently active, enrolled. Last updated 20 November 2025.

Last reviewed 2025-11-20 · How we verify

NCT05189730: ETNT

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Selected Chemotherapy Combined Immunotherapy Treated High Risk Patient After NCRT in Resected Locally Advanced ESCC

Active, enrolled Phase 2 Last updated 20 November 2025

What this trial tests

Phase 2 trial testing Tirelizumab in Esophageal Squamous Cell Carcinoma in 80 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

1 July 2021

Primary endpoint
31 January 2025

31 January 2027

Quick facts

Lead sponsor	Sichuan Cancer Hospital and Research Institute
Phase	Phase 2
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	80
Start date	1 July 2021
Primary completion	31 January 2025
Estimated completion	31 January 2027
Sites	1 location across China

Drugs / interventions tested

Tirelizumab — full drug profile →
Paclitaxel — full drug profile →
Carboplatin (Carboplatin) — full drug profile →
Neoadiuvant radiotherapy

Conditions studied

Esophageal Squamous Cell Carcinoma — all drugs for Esophageal Squamous Cell Carcinoma →

Sponsor

Sichuan Cancer Hospital and Research Institute

Who can join

Adults 18 to 75, any sex, with Esophageal Squamous Cell Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Tislelizumab combined with chemotherapy sequential neoadjuvant therapy for non-cCR patients after neoadjuvant chemoradiotherapy in locally advanced ESCC. And then the patients would receive surgery and adjuvant therapy according to the postoperative pathological results. It is expected that through this study, some high-risk patients could obtain better efficacy and prolong patient survival. At same time, low risk patients could avoid increasing perioperative complications and surgical risks, so that more patients could benefit from neoadjuvant treatment. The investigators aimed to explore a more accurate comprehensive treatment mode for patients with esophageal squamous cell carcinoma, and provide a certain scientific basis for the formulation of esophageal cancer diagnosis and treatment norms in China.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Neoadjuvant immunotherapy for resectable esophageal cancer: A review.
Li Q, Liu T, Ding Z. · · 2022 · cited 43× · PMID 36569908 · DOI 10.3389/fimmu.2022.1051841
Current state of the art: immunotherapy in esophageal cancer and gastroesophageal junction cancer.
Li N, Sohal D. · · 2023 · cited 22× · PMID 37995002 · DOI 10.1007/s00262-023-03566-5
Radiotherapy combined with immune checkpoint inhibitors in locally advanced/metastatic esophageal squamous cell carcinoma: clinical trials, efficacy and future directions.
Jiang M, Hu Y, Lin G, Chen C, et al · · 2023 · cited 18× · PMID 37325652 · DOI 10.3389/fimmu.2023.1177085
Perioperative immunotherapy for esophageal squamous cell carcinoma: Now and future.
Liu Y. · · 2023 · cited 16× · PMID 37753366 · DOI 10.3748/wjg.v29.i34.5020
Efficacy and safety of radiotherapy/chemoradiotherapy combined with immune checkpoint inhibitors for locally advanced stages of esophageal cancer: A systematic review and meta-analysis.
Wu J, Deng R, Ni T, Zhong Q, et al · · 2022 · cited 15× · PMID 35992797 · DOI 10.3389/fonc.2022.887525
Immunotherapy in the neoadjuvant treatment of gastrointestinal tumors: is the time ripe?
Gervaso L, Ciardiello D, Oliveira RA, Borghesani M, et al · · 2024 · cited 12× · PMID 38782539 · DOI 10.1136/jitc-2023-008027
Tislelizumab Plus Chemotherapy Sequential Neoadjuvant Therapy for Non-cCR Patients After Neoadjuvant Chemoradiotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma (ETNT): An Exploratory Study.
He W, Wang C, Wu L, Wan G, et al · · 2022 · cited 11× · PMID 35720312 · DOI 10.3389/fimmu.2022.853922
Immunotherapy during the Immediate Perioperative Period: A Promising Approach against Metastatic Disease.
Sandbank E, Eckerling A, Margalit A, Sorski L, et al · · 2023 · cited 10× · PMID 37623021 · DOI 10.3390/curroncol30080540

Verify or expand the search:

Other trials of Tirelizumab

Trials testing the same drug.

NCT06125080 — The Efficacy and Safety of Utidelone Plus Tirelizumab and Bevacizumab for Advanced or Metastatic Triple-negative Breast · Phase 2 · recruiting
NCT06122493 — Optimization of Treatment Strategy for Unresectable cN3 Esophageal Squamous Cell Carcinoma · Phase 2 · recruiting
NCT04819971 — Study of Perioperative Chemotherapy Combined With Tislelizumab and Trastuzumab in the Treatment of GC/EGC · Phase 2 · unknown
NCT05092217 — Tirelizumab Plus Surgery vs Surgery Alone for Recurrent Nasopharyngeal Carcinoma · Phase 2 · unknown

Other recruiting trials for Esophageal Squamous Cell Carcinoma

Currently open trials in the same condition.

NCT07503808 — A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types · Phase 1 · recruiting
NCT07385001 — A Prospective, Multicenter, Phase Ib/II Trial of Ivonescimab (AK112) Combined With Albumin-Paclitaxel and Cisplatin as N · Phase 1, PHASE2 · recruiting
NCT07217171 — A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial · Phase 1 · recruiting
NCT07109726 — A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations · Phase 1, PHASE2 · recruiting
NCT07090499 — A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors · Phase 1 · recruiting

Other Sichuan Cancer Hospital and Research Institute trials

Trials by the same sponsor.

NCT07269912 — Application of Multimodal MRI in Histological Grading and Prognostic Assessment of Rectal Cancer · not yet recruiting
NCT07082699 — The Efficacy of Antegrade and Retrograde Enemas Management in Low Anterior Resection Syndrome and Improving the Rate of · NA · not yet recruiting
NCT06939764 — Application of the sG8 Scale in Real-World Geriatric Oncology Patients · not yet recruiting
NCT06717854 — Retrograde and Antegrade Enema for Prevention of LARS After LAR: a Randomized Controlled Trial · NA · not yet recruiting
NCT06860685 — Trial of Gum Chewing to Enhance the Restoration of Intestinal Motility in Colorectal Cancer Surgery · Phase 1, PHASE2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05189730 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sichuan Cancer Hospital and Research Institute
Last refreshed: 20 November 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05189730.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing